For Healthcare Professionals

A Long-term Follow-up Study of Participants Who Received an Allogeneic CAR T-Cell Product

clipboard-pencil

About the study

The goal of this study is to collect information on the long-term safety of study participants who received Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in a Precision BioSciences, Inc. (PBI) Clinical Study. The main questions it aims to answer are: -What were the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)? Participants will visit a study center 3 times during the first year, and once per year after that for a physical exam and other assessments to check for CEI.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Receipt of at least 1 dose of PBCAR product in a PBI clinical study.
  2. A signed informed consent form (ICF).
  3. Willingness and ability to adhere to the study schedule and all other protocol requirements.

EXCLUSION CRITERIA

Exclusion Criteria:

* No unique exclusion criteria apply to this study.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 919-314-5512Email iconEmail Study Center

Study Details


Contition

Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study

Age

18 - 95

Participants Needed

75

Est. Completion Date

Dec 31, 2039

Treatment Type

OBSERVATIONAL


Sponsor

Precision BioSciences, Inc.

ClinicalTrials.gov NCT Identifier

NCT05822427

Study Number

PBCAR-LTF

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.